Mirabegron settlement costs and competition
The $90 million settlement (with $75 million amortized) will impact profitability, and potential generic entrants could erode market share.
LUPIN / Q3-FY26 / risks
Keep the risk register visible.
Lupin · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
high
US base business price erosion
Low single-digit price erosion in the US base business persists, which could offset volume gains if new product launches slow.
Biosimilar market competition
Increasing competition in biosimilars, including PBM private labels, could pressure margins despite Lupin's cost advantage.
Elixa development delays
The respiratory product Elixa has faced development delays; management expects material progress only in calendar 2026.